Twist Bioscience (NASDAQ:TWST) Given New $60.00 Price Target at Barclays

Twist Bioscience (NASDAQ:TWST) had its target price increased by Barclays from $45.00 to $60.00 in a research note published on Friday, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other research firms have also recently issued reports on TWST. Guggenheim began coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They set a buy rating and a $53.00 price target on the stock. Scotiabank raised their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a research note on Monday, May 6th. Evercore ISI raised their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an outperform rating in a research note on Friday, May 3rd. TD Cowen raised their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a buy rating in a research note on Thursday, June 13th. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an outperform rating in a research note on Friday, May 3rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and an average target price of $48.50.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $49.28 on Friday. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $55.26. The company’s 50-day moving average price is $43.84 and its 200 day moving average price is $38.27.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm’s revenue was up 25.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.06) EPS. Equities research analysts forecast that Twist Bioscience will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,732 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $49.41, for a total value of $85,578.12. Following the transaction, the chief executive officer now owns 505,846 shares in the company, valued at $24,993,850.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Patrick John Finn sold 2,174 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares in the company, valued at $5,307,324.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 1,732 shares of Twist Bioscience stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $49.41, for a total transaction of $85,578.12. Following the sale, the chief executive officer now owns 505,846 shares in the company, valued at approximately $24,993,850.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,426 shares of company stock worth $777,966. Company insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds have recently made changes to their positions in the company. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the fourth quarter valued at approximately $30,000. Federated Hermes Inc. purchased a new stake in shares of Twist Bioscience during the third quarter valued at approximately $29,000. Headlands Technologies LLC purchased a new stake in shares of Twist Bioscience during the first quarter valued at approximately $124,000. International Assets Investment Management LLC increased its stake in shares of Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after buying an additional 3,907 shares during the last quarter. Finally, Brown Advisory Inc. acquired a new stake in Twist Bioscience in the fourth quarter valued at $225,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.